Hydrogel: a new material for intravesical drug delivery after bladder cancer surgery

Wu, Yalong; Gu, Xinquan; Chen, Xiaoxi; Cui, Yongliang; Jiang, Wei; Liu, Bin

doi:10.1039/d3tb02837b

J. Mater. Chem. B

2024

DOI: 10.1039/d3tb02837b

|View full text |Cite

Hydrogel: a new material for intravesical drug delivery after bladder cancer surgery

Yalong Wu,

Xinquan Gu,

Xiaoxi Chen

et al.

Abstract: The standard treatment for non-muscle invasive bladder cancer (NMIBC) is transurethral resection of bladder tumor (TURBT).

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Hydrogel-based formulations for urothelial cancer therapy

Chang,

Chi,

Zheng

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Drug infusion therapy after surgery for urothelial carcinoma is an effective measure to reduce cancer recurrence rate. Hydrogels are drug carriers with good biocompatibility and high drug loading capacity, which can optimize the pharmacokinetics of drugs in the urinary system to improve the therapeutic effect. Compared with the traditional free drug in situ perfusion, the hydrogel drug loading system can still maintain effective drug concentration in the face of continuous urinary flushing due to its good mucosal adhesion effect. The significantly prolonged drug retention time can not only improve the therapeutic effect of drugs, but also reduce the discomfort and risk of urinary tract infections caused by frequent drug infusion, and improve patient compliance. In addition, the combination of hydrogel with nanoparticles and magnetic materials can also improve the mucosal permeability and targeting effect of the hydrogel drug loading system, so as to overcome the mucus layer of urinary epithelium and the physiological barrier of tumor and minimize the impact on normal tissue and cell functions. At present, the research of hydrogels for urothelial cancer treatment involves chemotherapy, immunotherapy, gene therapy, inhibition of metabolism and multi strategy synergistic therapy. This review summarizes the research progress of hydrogels for the treatment of urothelial carcinoma, hoping to provide a reference for the future research of safe, reliable, effective, and advanced hydrogels with little side effects.

show abstract

Hydrogel-based formulations for urothelial cancer therapy

Chang,

Chi,

Zheng

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Hydrogel: a new material for intravesical drug delivery after bladder cancer surgery

Abstract: The standard treatment for non-muscle invasive bladder cancer (NMIBC) is transurethral resection of bladder tumor (TURBT).

Cited by 1 publication

References 100 publications

Hydrogel-based formulations for urothelial cancer therapy

Hydrogel-based formulations for urothelial cancer therapy

Contact Info

Product

Resources

About